Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.55 |
| ▸ | PPARA | Q07869 | 12/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661012 | 0.91 | PPARA (0.42) | PPARGPPARAPPARDBCL2MCL1 | |
| SCHEMBL5659260 | 0.90 | PPARG (0.51) | PPARGPPARAPPARDBCL2MCL1 | |
| SCHEMBL5660872 | 0.90 | PPARA (0.51) | PPARGPPARAPPARDBCL2MCL1 | |
| SCHEMBL5660099 | 0.89 | PPARA (0.43) | PPARGPPARAPPARD | |
| SCHEMBL5660995 | 0.85 | MCL1 (0.47) | PPARGPPARAPPARDBCL2MCL1 | |
| SCHEMBL5659236 | 0.84 | PTGDR2 (0.41) | BCL2MCL1GRM2 | |
| SCHEMBL14548501 | 0.83 | BCL2 (0.42) | PPARGPPARAPPARDBCL2MCL1 | |
| SCHEMBL5662960 | 0.82 | MTNR1A (0.43) | PPARGPPARAPPARDMCL1FBP1 | |
| SCHEMBL14526421 | 0.82 | PPARA (0.71) | PPARGPPARAFBP1GRM2 | |
| SCHEMBL5661036 | 0.81 | PPARA (0.35) | PPARGPPARAPPARDBCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | PPARG 170/4885PPARA 251/4885PPARD 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.